Radcliffe Capital Management’s Frazier Lifesciences Acquisition Corporation Warrant FLACW Stock Holding History

Radcliffe Capital Management’s Portfolio FLACW Stock Details FLACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-70,000	Closed	-$698K	–	1137
2022 Q3	$698K	Sell	70,000 -13,333	-16%	-$8.46K	0.02%	1015
2022 Q2	$822K	Hold	83,333	–	–	0.02%	1032
2022 Q1	$820K	Hold	83,333	–	–	0.02%	1030
2021 Q4	$812K	Hold	83,333	–	–	0.02%	894
2021 Q3	$816K	Hold	83,333	–	–	0.02%	757
2021 Q2	$813K	Hold	83,333	–	–	0.03%	776
2021 Q1	$830K	Buy	+83,333	New	+$141K	0.03%	602

Radcliffe Capital Management's FLACW Position: Q4 2022 in Review

Radcliffe Capital Management sold out of Frazier Lifesciences Acquisition Corporation Warrant (FLACW) in Q4 2022, closing a stake of 70,000 shares — an estimated $698K sold.

Radcliffe Capital Management first reported a position in FLACW in Q1 2021 and held it in 7 quarters. The position peaked at $830K in Q1 2021. 0 funds tracked by Wall St. Rank hold FLACW as of Q4 2022.

Radcliffe Capital Management reported no remaining Frazier Lifesciences Acquisition Corporation Warrant position as of Q4 2022 after selling out during the quarter.
Radcliffe Capital Management sold 70,000 Frazier Lifesciences Acquisition Corporation Warrant shares in Q4 2022, an estimated $698K.
Radcliffe Capital Management first reported a position in Frazier Lifesciences Acquisition Corporation Warrant in Q1 2021 and held it in 7 quarters.
Radcliffe Capital Management's Frazier Lifesciences Acquisition Corporation Warrant position peaked at $830K in Q1 2021.
0 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Warrant as of Q4 2022.

Based on Radcliffe Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.